Advertisement

Vivos Therapeutics, Inc. VVOS

Set alert

Price alert · VVOS

All alert types
0.11 USD -0.01 -5.64%

At close · Oct 30

0.11 0.00 +0.62%

After hours · Oct 30, 7:31 PM ET

Bid
0.11 × 1
Ask
0.12 × 2
0.111 Day range 0.1191
0.1138 52-week range 2.59
YTD
-94.39%
1 year
-95.59%
Open
0.115
Prev close
0.1206
Mkt cap
3.82M
Vol
741.95K
Avg vol
15.03M
EPS
-1.88
P/E
0.00
Div yield
0.00%
More statistics
Low
0.111
High
0.1191
Forward P/E
-9.31
Beta
7.68
Short ratio
0.66
Inst. own
13.72%
Dividend
0.00
Ex-div date
Earnings
Aug 14, 2024
50-d avg
3.32
200-d avg
2.88
1y target
6.30

MAX chart

Chart tools
Interval

Events in this range
  • Oct 27, 2023Split: 1 for 25
  • Mar 28, 2024Earnings: -3.05; estimate 0; surprise —%
  • May 14, 2024Earnings: -1.63; estimate 0; surprise —%
  • May 14, 2024Earnings: —; estimate 0; surprise —%
  • Aug 14, 2024Earnings: -0.6; estimate 0; surprise —%
  • Aug 14, 2024Earnings: —; estimate 0; surprise —%
  • Aug 20, 2024Rating: Ascendiant Capital · Buy → Buy
  • Nov 14, 2024Earnings: -0.4; estimate -0.7; surprise 42.86%
  • Nov 19, 2024Rating: Alliance Global Partners · Buy → Buy
  • Nov 20, 2024Rating: Ascendiant Capital · Buy → Buy
Signals (76)
NameDateAgo
RSI: OversoldJun 15, 20264 months ago
SMA: BearishJun 8, 20264 months ago
SMA: BullishJun 1, 20265 months ago
MACD: Buy SignalMay 25, 20265 months ago
MACD: Sell SignalApr 20, 20266 months ago
RSI: OversoldApr 20, 20266 months ago
MACD: Buy SignalApr 6, 20266 months ago
SMA: BearishJan 5, 202610 months ago
SMA: BullishDec 29, 202510 months ago
SMA: BearishSep 8, 20251 year ago
MACD: Sell SignalSep 8, 20251 year ago
SMA: BearishAug 11, 20251 year ago
RSI: OverboughtJul 7, 20251 year ago
SMA: BullishJun 30, 20251 year ago
MACD: Buy SignalJun 23, 20251 year ago
SMA: BullishJun 16, 20251 year ago
SMA: BearishMay 12, 20251 year ago
SMA: BullishMay 5, 20251 year ago
SMA: BearishMar 24, 20251 year ago
SMA: BullishMar 17, 20251 year ago
SMA: BearishMar 10, 20251 year ago
SMA: BullishFeb 24, 20251 year ago
SMA: BearishFeb 17, 20251 year ago
MACD: Sell SignalFeb 17, 20251 year ago
SMA: BearishJan 27, 20251 year ago
SMA: BullishNov 4, 20241 year ago
SMA: BullishOct 14, 20242 years ago
SMA: BearishSep 30, 20242 years ago
SMA: BearishSep 23, 20242 years ago
SMA: BullishSep 9, 20242 years ago
SMA: BullishAug 12, 20242 years ago
SMA: BearishJul 29, 20242 years ago
SMA: BullishJul 1, 20242 years ago
MACD: Buy SignalJun 10, 20242 years ago
MACD: Sell SignalJan 22, 20242 years ago
SMA: BearishJan 8, 20242 years ago
SMA: BearishJan 8, 20242 years ago
SMA: BullishNov 27, 20232 years ago
SMA: BullishNov 27, 20232 years ago
RSI: OverboughtNov 27, 20232 years ago
MACD: Buy SignalNov 13, 20232 years ago
MACD: Sell SignalNov 6, 20232 years ago
SMA: BearishOct 23, 20233 years ago
SMA: BullishOct 2, 20233 years ago
SMA: BearishJul 10, 20233 years ago
SMA: BullishMay 22, 20233 years ago
MACD: Buy SignalMay 22, 20233 years ago
MACD: Sell SignalMar 6, 20233 years ago
SMA: BearishFeb 13, 20233 years ago
SMA: BearishFeb 6, 20233 years ago
SMA: BullishJan 2, 20233 years ago
SMA: BullishJan 2, 20233 years ago
RSI: OversoldNov 28, 20223 years ago
MACD: Buy SignalOct 17, 20224 years ago
MACD: Sell SignalSep 26, 20224 years ago
RSI: OversoldSep 26, 20224 years ago
MACD: Buy SignalJul 4, 20224 years ago
MACD: Sell SignalJun 20, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BullishMay 30, 20224 years ago
MACD: Buy SignalMay 30, 20224 years ago
MACD: Sell SignalApr 18, 20224 years ago
SMA: BearishMar 21, 20224 years ago
MACD: Buy SignalJan 24, 20224 years ago
SMA: BullishJan 17, 20224 years ago
MACD: Sell SignalNov 15, 20214 years ago
SMA: BearishSep 27, 20215 years ago
MACD: Buy SignalAug 30, 20215 years ago
SMA: BullishAug 23, 20215 years ago
RSI: OversoldJul 26, 20215 years ago
SMA: BearishApr 19, 20215 years ago
SMA: BullishMar 29, 20215 years ago
SMA: BearishMar 15, 20215 years ago
SMA: BullishMar 8, 20215 years ago
SMA: BearishMar 1, 20215 years ago
SMA: BullishFeb 15, 20215 years ago

Key statistics

Market cap
24.76M
Enterprise value
4.52M
Trailing P/E
0.00
Forward P/E
-9.31
PEG ratio
0.00
Price / sales
1.77
Price / book
22.86
EPS (TTM)
-4.99
Beta
7.68
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-85.90%
Revenue (TTM)
14.02M
Revenue growth
19.40%
Free cash flow
-8.90M
Total cash
6.90M
Total debt
1.76M
Return on equity
-284.96%
Shares outstanding
4.84M
Short % of float
2.01%
50-day average
3.32
200-day average
2.88

Analyst view

Consensus: none

Price target (mean) 6.30 +5436.0% upside
Target (low)
6.00
Target (mean)
6.30
Target (high)
6.60
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 14, 2024

Expected Aug 14, 2024. Consensus EPS estimate -0.43.

Earnings history

Financials — quick view

All financials
VVOS Revenue — quarterly 5.15M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VVOS Net income — quarterly -5.48M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
VVOS EPS — quarterly -0.31
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

VVOS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.70-0.40+0.30+42.86%
Aug 14, 2024Jun 1, 20240.00-0.60——
Aug 14, 2024Jun 1, 20240.00———
May 14, 2024Mar 1, 20240.00-1.63——
May 14, 2024Mar 1, 20240.00———
Mar 28, 2024Dec 1, 20230.00-3.05——

Upgrades / downgrades

VVOS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2024Ascendiant CapitalreitBuyBuy
Nov 19, 2024Alliance Global PartnersmainBuyBuy
Aug 20, 2024Ascendiant CapitalmainBuyBuy

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
vivos.com

News

Your note

Sign in to keep a note on VVOS — it syncs with the Stock Master app.

Insider holders

VVOS insider holders
InsiderRelationLatest transactionDateShares held
HUNTSMAN RONALD KIRKChief Executive OfficerPurchaseJun 19, 20231,826,520

Institution ownership

VVOS institution ownership
Holder% heldSharesValueReported
Strategic Wealth Investment Group, LLC2.07%100,000512.00KSep 29, 2024
Geode Capital Management, LLC0.60%28,802147.47KSep 29, 2024
OMERS Administration Corporation0.52%25,000128.00KSep 29, 2024
Commonwealth Equity Services, LLC0.43%21,000107.52KSep 29, 2024
Sabby Management, LLC0.42%20,502104.97KSep 29, 2024
Two Sigma Investments, LP0.42%20,482104.87KSep 29, 2024

Fund ownership

VVOS fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.38%18,24793.42KOct 30, 2024
Vanguard Extended Market Index Fund0.22%10,57954.16KSep 29, 2024
Fidelity Total Market Index Fund0.12%5,82529.82KOct 30, 2024
Fidelity Series Total Market Index Fund0.12%5,66729.02KOct 30, 2024
Advertisement